PET scans may help supercharge immune cell therapy against melanoma

NCT ID NCT07700121

Not yet recruiting Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This pilot study explores whether a special PET/CT scan that tracks CD8 immune cells can help select the best tumors for harvesting immune cells (TILs) to treat stage IV melanoma. Participants receive the TIL therapy lifileucel (AMTAGVI) after a chemotherapy regimen. The goal is to see if tumors with higher CD8 activity yield more effective TILs, potentially improving response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lifileucel (AMTAGVI) and Zr-89 crefmirlimab berdoxam
What this could lead to: If successful, this approach could make TIL therapy more effective for people with advanced melanoma by identifying which tumors are most likely to respond.
What could go wrong: This is a very early pilot study with only 10 participants, so results may not apply broadly. The procedure involves surgery and chemotherapy, which carry risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE OR METASTATIC MELANOMA

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.